Linda A.Hesse

Linda Hesse advises clients in the areas of capital markets, securities law, public M&A, and corporate governance under both U.S. and French law. She acts for issuers with respect to their issuances of debt and equity securities; listings on Euronext, Nasdaq, and the NYSE; and on regulatory matters involving the SEC and the French Financial Markets Authority (AMF). Linda also advises financial institutions as advisors in offerings of equity, debt, and complex instruments. Her practice includes advising on environmental, social, and governance (ESG) matters, including sustainable finance transactions, green frameworks, ESG disclosures, and risk assessments.

​Notable issuer clients include Orange since its IPO and for ongoing securities compliance, debt and equity offerings, and M&A; Sanofi on its ongoing SEC compliance and U.S. shelf program, including its $7 billion Yankee bond offering in connection with its Genzyme acquisition, the spin-off of EUROAPI, and the separation of its Consumer Healthcare business, Opella; and EDAP TMS, Innate Pharma, and Genfit on ongoing securities compliance and equity offerings.

​Investment bank clients include BNP Paribas, Crédit Agricole CIB, and Natixis. Notable underwriter engagements include representing the underwriters on Genfit's Nasdaq IPO (with respect to French law), Medincell's IPO on Euronext Paris, and Sequans' NYSE IPO.​

Linda also advises companies on cross-border public M&A transactions, including Sega on its acquisition of Rovio Entertainment; Panalpina on its acquisition by DSV; Stallergenes Greer in connection with the take private transaction by Waypoint; Kildare Partners on its acquisition of Technopolis Plc; Safran on its acquisition of Zodiac Aerospace; TotalEnergies on its investment in Clean Energy Fuels; and Orange on the Jazztel acquisition.